Lantheus (NASDAQ:LNTH) Trading 4.4% Higher – Here’s What Happened

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s share price shot up 4.4% during mid-day trading on Monday . The company traded as high as $110.98 and last traded at $111.01. 721,991 shares were traded during trading, a decline of 21% from the average session volume of 916,695 shares. The stock had previously closed at $106.34.

Wall Street Analyst Weigh In

Several research analysts recently commented on LNTH shares. Truist Financial lifted their price target on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. JMP Securities reissued a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $132.86.

Lantheus Trading Up 3.5 %

The business has a 50-day moving average price of $90.71 and a 200-day moving average price of $96.82. The firm has a market cap of $7.53 billion, a P/E ratio of 18.30 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. On average, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Transactions at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Lantheus

Large investors have recently made changes to their positions in the business. Farther Finance Advisors LLC increased its position in Lantheus by 226.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 758 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 526 shares in the last quarter. Assetmark Inc. increased its holdings in shares of Lantheus by 11.4% during the third quarter. Assetmark Inc. now owns 62,802 shares of the medical equipment provider’s stock valued at $6,893,000 after acquiring an additional 6,442 shares in the last quarter. Atria Investments Inc purchased a new position in shares of Lantheus in the 3rd quarter valued at approximately $330,000. Crossmark Global Holdings Inc. boosted its stake in Lantheus by 11.5% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 4,935 shares of the medical equipment provider’s stock worth $542,000 after purchasing an additional 510 shares in the last quarter. Finally, Chartwell Investment Partners LLC grew its position in Lantheus by 58.8% during the 3rd quarter. Chartwell Investment Partners LLC now owns 35,800 shares of the medical equipment provider’s stock worth $3,929,000 after purchasing an additional 13,257 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.